INM

SEC source: 0001213900-22-080983 · ownership.xml · derivative · entry 1

WOUDENBERG MICHAEL · CIK 0001817884 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,342

Underlying: Common shares · 7,500 shares

Expires 2027-12-15

F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

SEC source: 0001213900-22-080962 · ownership.xml · derivative · entry 1

Baldasare Bryan T · CIK 0001761920 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

Underlying: Common shares · 840 shares

Expires 2027-12-15

F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: Vesting 100% on the one-year anniversary of the grant date (Dec 16, 2023) or immediately prior to the next AGM, whichever is sooner.

F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

SEC source: 0001213900-22-080969 · ownership.xml · derivative · entry 1

Grove Janet P · CIK 0001355675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

Underlying: Common shares · 840 shares

Expires 2027-12-15

F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: Vesting 100% on the one-year anniversary of the grant date (Dec 16, 2023) or immediately prior to the next AGM, whichever is sooner.

F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

SEC source: 0001213900-22-080987 · ownership.xml · derivative · entry 1

Lemerond Nicole · CIK 0001941712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

Underlying: Common shares · 840 shares

Expires 2027-12-15

F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: Vesting 100% on the one-year anniversary of the grant date (Dec 16, 2023) or immediately prior to the next AGM, whichever is sooner.

F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

SEC source: 0001213900-22-080971 · ownership.xml · derivative · entry 1

Tegge Jonathan · CIK 0001755310 · Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,400

Underlying: Common shares · 1,400 shares

Expires 2027-12-15

F1 · derivative.exercise_date: Vesting 1/12 per month, in arrears, for 12 months.

SEC source: 0001213900-22-080992 · ownership.xml · derivative · entry 1

Johnson Shane Aaron · CIK 0001889332 · Sr VP & General Manager

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common shares · 4,200 shares

Expires 2027-12-15

F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

SEC source: 0001213900-22-072923 · ownership.xml · derivative · entry 1

WOUDENBERG MICHAEL · CIK 0001817884 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,342

Underlying: Common shares · 7,500 shares

Expires 2027-11-13

F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

SEC source: 0001213900-22-072922 · ownership.xml · derivative · entry 1

HSU ERIC C · CIK 0001817867 · Sr. VP, Pre-Clinical Res/Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,878

Underlying: Common shares · 4,200 shares

Expires 2027-11-13

F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

SEC source: 0001213900-22-072920 · ownership.xml · derivative · entry 1

ADAMS ERIC A · CIK 0001817882 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,502

Underlying: Common shares · 15,000 shares

Expires 2027-11-13

F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

SEC source: 0001213900-22-072918 · ownership.xml · derivative · entry 1

MANCINI ALEXANDRA DIANE JANET · CIK 0001817890 · Sr VP, Clinical Reg Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,152

Underlying: Common shares · 4,200 shares

Expires 2027-11-13

F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

SEC source: 0001213900-22-072924 · ownership.xml · derivative · entry 1

Johnson Shane Aaron · CIK 0001889332 · Sr. VP & General Manager

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common shares · 4,200 shares

Expires 2027-11-13

F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

SEC source: 0001213900-22-073944 · ownership.xml · derivative · entry 1

HSU ERIC C · CIK 0001817867 · Sr. VP, Pre-Clinical Res/Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,678

Underlying: Common shares · 4,200 shares

Expires 2027-11-13

F3 · kind: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 4,678 derivative securities of the Issuer.

F3 · shares: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 4,678 derivative securities of the Issuer.

F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the Issuer's common stock was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

F3 · balance_after: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 4,678 derivative securities of the Issuer.

SEC source: 0001213900-22-073945 · ownership.xml · derivative · entry 1

MANCINI ALEXANDRA DIANE JANET · CIK 0001817890 · Sr VP, Clinical Reg Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,952

Underlying: Common shares · 4,200 shares

Expires 2027-11-13

F3 · kind: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,952 derivative securities of the Issuer.

F3 · shares: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,952 derivative securities of the Issuer.

F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the Issuer's common stock was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

F3 · balance_after: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,952 derivative securities of the Issuer.

SEC source: 0001213900-22-073943 · ownership.xml · derivative · entry 1

ADAMS ERIC A · CIK 0001817882 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,502

Underlying: Common shares · 15,000 shares

Expires 2027-11-13

F3 · kind: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 15,000 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 13,502 derivative securities of the Issuer.

F3 · shares: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 15,000 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 13,502 derivative securities of the Issuer.

F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the Issuer's common stock was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

F3 · balance_after: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 15,000 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 13,502 derivative securities of the Issuer.

SEC source: 0001213900-22-073942 · ownership.xml · derivative · entry 1

WOUDENBERG MICHAEL · CIK 0001817884 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,842

Underlying: Common shares · 7,500 shares

Expires 2027-11-13

F3 · kind: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 7,500 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,842 derivative securities of the Issuer.

F3 · shares: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 7,500 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,842 derivative securities of the Issuer.

F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the Issuer's common stock was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

F3 · balance_after: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 7,500 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,842 derivative securities of the Issuer.

SEC source: 0001213900-22-073946 · ownership.xml · derivative · entry 1

Johnson Shane Aaron · CIK 0001889332 · Sr VP & General Manager

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,800

Underlying: Common shares · 4,200 shares

Expires 2027-11-13

F3 · kind: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,800 derivative securities of the Issuer.

F3 · shares: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,800 derivative securities of the Issuer.

F1 · derivative.exercise_date: The options were granted on 11/14/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

F2 · balance_after: On September 7, 2022, the Issuer's common stock was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

F3 · balance_after: On November 14, 2022, the reporting person reported the grant of an employee stock option to buy 4,200 shares of the Issuer's common stock at an exercise price of $2.78 per share. Such employee stock option was issued in error and has been cancelled. As of November 18, 2022, the reporting person beneficially owns 3,800 derivative securities of the Issuer.

SEC source: 0001213900-22-046530 · ownership.xml · derivative · entry 1

Lemerond Nicole · CIK 0001941712 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common shares · 14,000 shares

Expires 2027-08-10

F1 · derivative.exercise_date: The options were granted on Aug 10, 2022 and will vest monthly, in arrears, as follows: (i) 390 stock options will vest on the 10th day of each month for 35 months, and (ii) 350 stock options will vest on Aug 10, 2025 (the three year anniversary of Grant date).

SEC source: 0001213900-22-030914 · ownership.xml · derivative · entry 1

ADAMS ERIC A · CIK 0001817882 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,576

Underlying: Common shares · 13,636 shares

Expires 2022-06-02

F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$14.85 using an exchange rate of C$1.2639 = $US1.00

SEC source: 0001213900-22-030915 · ownership.xml · derivative · entry 1

MANCINI ALEXANDRA DIANE JANET · CIK 0001817890 · Sr VP, Clinical Reg Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,787

Underlying: Common shares · 1,515 shares

Expires 2022-06-02

F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$14.85 using an exchange rate of C$1.2639 = $US1.00

SEC source: 0001213900-22-028300 · ownership.xml · derivative · entry 1

Baldasare Bryan T · CIK 0001761920 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Shares · 14,000 shares

Expires 2027-05-16

F1 · derivative.exercise_date: The options were granted on May 17, 2022 and will vest monthly, in arrears, as follows: (i) 390 stock options will vest on the 17th day of each month for 35 months, and (ii) 350 stock options will vest on May 17, 2025 (the three year anniversary of Grant date).

SEC source: 0001213900-22-020314 · ownership.xml · nonDerivative · entry 1

ADAMS ERIC A · CIK 0001817882 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,003

SEC source: 0001213900-22-019688 · ownership.xml · nonDerivative · entry 1

ADAMS ERIC A · CIK 0001817882 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,843

SEC source: 0001213900-22-009673 · ownership.xml · derivative · entry 1

WOUDENBERG MICHAEL · CIK 0001817884 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,060

Underlying: Common shares · 5,000 shares

Expires 2027-02-22

F1 · derivative.exercise_date: The options were granted on 2/23/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

SEC source: 0001213900-22-008983 · ownership.xml · derivative · entry 1

MANCINI ALEXANDRA DIANE JANET · CIK 0001817890 · Sr VP, Clinical Reg Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,302

Underlying: Common shares · 3,030 shares

Expires 2022-02-20

F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$12.21 using an exchange rate of C$1.2734 = $US1.00

SEC source: 0001213900-22-008775 · ownership.xml · derivative · entry 1

Grove Janet P · CIK 0001355675 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common shares · 14,000 shares

Expires 2027-02-17

F1 · derivative.exercise_date: The options were granted on 02/18/2022 with 390 stock options vesting on the 18th day of each of the 35 months commencing March 18, 2022 through January 18, 2025 and 350 stock options will vest on February 18, 2025.

SEC source: 0001213900-22-003333 · ownership.xml · derivative · entry 2

ADAMS ERIC A · CIK 0001817882 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 351,212

Underlying: Common shares · 60,606 shares

Expires 2022-01-24

F2 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$3.63 using an exchange rate of C$1.2554 = $US1.00

SEC source: 0001213900-22-003333 · ownership.xml · derivative · entry 1

ADAMS ERIC A · CIK 0001817882 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 411,818

Underlying: Common shares · 60,606 shares

Expires 2022-01-24

F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$2.64 using an exchange rate of C$1.2554 = $US1.00

SEC source: 0001213900-22-003332 · ownership.xml · derivative · entry 1

MANCINI ALEXANDRA DIANE JANET · CIK 0001817890 · Sr VP, Clinical Reg Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,332

Underlying: Common shares · 12,121 shares

Expires 2022-01-24

F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$6.44 using an exchange rate of C$1.2554 = $US1.00

SEC source: 0001213900-22-003331 · ownership.xml · derivative · entry 1

HULL ANDREW · CIK 0001818252 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,122

Underlying: Common shares · 30,303 shares

Expires 2022-01-24

F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$3.63 using an exchange rate of C$1.2554 = $US1.00

SEC source: 0001213900-22-003286 · ownership.xml · nonDerivative · entry 1

COLWILL BRUCE · CIK 0001817743 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,515

SEC source: 0001213900-22-003334 · ownership.xml · derivative · entry 1

Garner William J · CIK 0001407235 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,122

Underlying: Common shares · 24,242 shares

Expires 2022-01-24

F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$4.29 using an exchange rate of C$1.2554 = $US1.00

SEC source: 0001213900-22-003330 · ownership.xml · derivative · entry 3

Cutler Adam D. · CIK 0001722673 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,122

Underlying: Common shares · 22,727 shares

Expires 2022-01-24

F3 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$3.63 using an exchange rate of C$1.2554 = $US1.00

SEC source: 0001213900-22-003330 · ownership.xml · derivative · entry 2

Cutler Adam D. · CIK 0001722673 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,849

Underlying: Common shares · 1,515 shares

Expires 2022-01-24

F2 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$4.62 using an exchange rate of C$1.2554 = $US1.00

SEC source: 0001213900-22-003330 · ownership.xml · derivative · entry 1

Cutler Adam D. · CIK 0001722673 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,364

Underlying: Common shares · 6,061 shares

Expires 2022-01-24

F1 · derivative.exercise_price: Converted from the Canadian dollar exercise price of C$4.79 using an exchange rate of C$1.2554 = $US1.00

SEC source: 0001213900-22-001005 · ownership.xml · nonDerivative · entry 1

Johnson Shane Aaron · CIK 0001889332 · SVP, GM of BayMedica LLC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,595

SEC source: 0001213900-21-068212 · ownership.xml · nonDerivative · entry 1

Johnson Shane Aaron · CIK 0001889332 · SVP, GM of BayMedica LLC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 296,095

SEC source: 0001213900-21-068184 · ownership.xml · derivative · entry 1

HULL ANDREW · CIK 0001818252 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,425

Underlying: Common shares · 7,000 shares

Expires 2026-12-28

F1 · derivative.exercise_date: The options were granted on 12/29/2021 and will vest 100% on the one year anniversary of the grant date (Dec 29, 2022) or immediately prior to the next AGM, whichever is sooner.

SEC source: 0001213900-21-068183 · ownership.xml · derivative · entry 1

Garner William J · CIK 0001407235 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,364

Underlying: Common shares · 7,000 shares

Expires 2026-12-28

F1 · derivative.exercise_date: The options were granted on 12/16/2020 and will vest 100% on the one year anniversary of the grant date (Dec 16, 2021) or immediately prior to the next AGM, whichever is sooner.

SEC source: 0001213900-21-068185 · ownership.xml · derivative · entry 1

Sazdanoff Catherine · CIK 0001650901 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,091

Underlying: Common shares · 7,000 shares

Expires 2026-12-28

F1 · derivative.exercise_date: The options were granted on 12/29/2021 and will vest 100% on the one year anniversary of the grant date (Dec 29, 2022) or immediately prior to the next AGM, whichever is sooner.

SEC source: 0001213900-21-068182 · ownership.xml · derivative · entry 1

Cutler Adam D. · CIK 0001722673 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,425

Underlying: Common shares · 7,000 shares

Expires 2026-12-28

F1 · derivative.exercise_date: The options were granted on 12/29/2021 and will vest 100% on the one year anniversary of the grant date (Dec 29, 2022) or immediately prior to the next AGM, whichever is sooner.

SEC source: 0001213900-21-059271 · ownership.xml · nonDerivative · entry 1

Johnson Shane Aaron · CIK 0001889332 · SVP, GM of BayMedica LLC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,002

SEC source: 0001213900-21-053585 · ownership.xml · derivative · entry 1

HSU ERIC C · CIK 0001817867 · Sr. VP, Pre-Clinical Res/Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,969

Underlying: Common shares · 35,000 shares

Expires 2026-10-17

F1 · derivative.exercise_date: The options were granted on 10/18/2021 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

SEC source: 0001213900-21-053575 · ownership.xml · derivative · entry 1

MANCINI ALEXANDRA DIANE JANET · CIK 0001817890 · Sr VP, Clinical Reg Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,453

Underlying: Common shares · 35,000 shares

Expires 2026-10-17

F1 · derivative.exercise_date: The options were granted on 10/18/2021 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

SEC source: 0001213900-21-053583 · ownership.xml · derivative · entry 1

ADAMS ERIC A · CIK 0001817882 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 472,424

Underlying: Common shares · 125,000 shares

Expires 2026-10-17

F1 · derivative.exercise_date: The options were granted on 10/18/2021 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

SEC source: 0001213900-21-053587 · ownership.xml · derivative · entry 1

WOUDENBERG MICHAEL · CIK 0001817884 · VP, Chem/Manufacturing/Control

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,060

Underlying: Common shares · 30,000 shares

Expires 2026-10-17

F1 · derivative.exercise_date: The options were granted on 10/18/2021 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

SEC source: 0001213900-21-053578 · ownership.xml · derivative · entry 1

COLWILL BRUCE · CIK 0001817743 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,303

Underlying: Common shares · 60,000 shares

Expires 2026-10-17

F1 · derivative.exercise_date: The options were granted on 10/18/2021 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.

SEC source: 0001213900-21-050751 · ownership.xml · nonDerivative · entry 1

ADAMS ERIC A · CIK 0001817882 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,283

SEC source: 0001213900-21-050522 · ownership.xml · nonDerivative · entry 1

ADAMS ERIC A · CIK 0001817882 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,483

SEC source: 0001213900-21-050521 · ownership.xml · nonDerivative · entry 1

COLWILL BRUCE · CIK 0001817743 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,515

SEC source: 0001213900-20-043364 · ownership.xml · derivative · entry 1

HSU ERIC C · CIK 0001817867 · Sr. VP, Pre-Clinical Res/Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common shares · 35,000 shares

Expires 2025-12-15

F1 · derivative.exercise_price: The Canadian exercise price of C$3.85 was converted into U.S. dollars using an exchange rate of C$1.2753 = US$1.00.

F2 · derivative.exercise_date: The options were granted on 12/16/2020 and will vest as follows: 25% on 6/16/2021; 25% on 12/16/2021; 25% on 6/16/2022; and 25% on 12/16/2022.